Xerava (Eravacycline Di-Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Xerava (Eravacycline Di-Hydrochloride) by Tetraphase: FDA Orange Book core substance LOE 2037-10-19, 0 AB generics, $961K 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTetraphase
FDA Application & PathwayN211109 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-10-19
Last Listed Patent or Exclusivity Date2037-10-19
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$961K
2024 Medicare Part D Spend$690K
2024 Medicaid Spend$271K
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 27.9% 2-yr change)